CY1113182T1 - Συνθεσεις και μεθοδοι για την αντιμετωπιση ιογενους λοιμωξης - Google Patents

Συνθεσεις και μεθοδοι για την αντιμετωπιση ιογενους λοιμωξης

Info

Publication number
CY1113182T1
CY1113182T1 CY20121100586T CY121100586T CY1113182T1 CY 1113182 T1 CY1113182 T1 CY 1113182T1 CY 20121100586 T CY20121100586 T CY 20121100586T CY 121100586 T CY121100586 T CY 121100586T CY 1113182 T1 CY1113182 T1 CY 1113182T1
Authority
CY
Cyprus
Prior art keywords
methods
virusal
infection
compositions
treatment
Prior art date
Application number
CY20121100586T
Other languages
English (en)
Inventor
Peter Andreas Nicolai Reumert Wagtmann
Francois Romagne
Joakim Glamann
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of CY1113182T1 publication Critical patent/CY1113182T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε νέες συνθέσεις και μεθόδους ρύθμισης της ανοσοαντίδρασης σε ένα άτομο. Ειδικότερα, η εφεύρεση αναφέρεται σε ειδικά αντισώματα που ρυθμίζουν την ενεργότητα των κυττάρων ΝΚ και επιτρέπουν την ενίσχυση της κυτταροτοξικότητας των κυττάρων ΝΚ σε θηλαστικά άτομα. Η εφεύρεση επίσης αναφέρεται σε τμήματα και παράγωγα τέτοιων αντισωμάτων, όπως επίσης σε φαρμακευτικές συνθέσεις που περιλαμβάνουν τα ανωτέρω και στη χρήση τους, ιδιαιτέρως σε θεραπεία, ώστε να αυξάνουν την ενεργότητα ή την κυτταροτοξικότητα των ΝΚ κυττάρων στα άτομα.
CY20121100586T 2005-01-06 2012-06-29 Συνθεσεις και μεθοδοι για την αντιμετωπιση ιογενους λοιμωξης CY1113182T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500027 2005-01-06
EP06700714A EP1835937B1 (en) 2005-01-06 2006-01-06 Compositions and methods for treating viral infection

Publications (1)

Publication Number Publication Date
CY1113182T1 true CY1113182T1 (el) 2016-04-13

Family

ID=36593628

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100586T CY1113182T1 (el) 2005-01-06 2012-06-29 Συνθεσεις και μεθοδοι για την αντιμετωπιση ιογενους λοιμωξης

Country Status (11)

Country Link
US (2) US8551483B2 (el)
EP (1) EP1835937B1 (el)
JP (1) JP5154949B2 (el)
AT (1) ATE552852T1 (el)
CY (1) CY1113182T1 (el)
DK (1) DK1835937T3 (el)
ES (1) ES2384466T3 (el)
PL (1) PL1835937T3 (el)
PT (1) PT1835937E (el)
SI (1) SI1835937T1 (el)
WO (1) WO2006072624A2 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004030464D1 (de) 2003-07-02 2011-01-20 Innate Pharma Methode zur produktion und evaluierung der zytotoxizität von kir2dl nk-rezeptor antikörpern
US20090191213A9 (en) * 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
AU2005259221B2 (en) * 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US20110280849A1 (en) * 2010-03-26 2011-11-17 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
JP6342325B2 (ja) * 2011-05-25 2018-06-13 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 炎症性障害の治療のための抗ｋｉｒ抗体
JPWO2014189138A1 (ja) * 2013-05-23 2017-02-23 Ｉｄａｃセラノスティクス株式会社 免疫不全ウイルス感染の治療又は予防剤
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
JP7062361B2 (ja) 2014-05-27 2022-05-06 アカデミア シニカ 抗ｈｅｒ２糖操作抗体群およびその使用
CN106573971A (zh) 2014-05-27 2017-04-19 中央研究院 抗cd20醣抗体及其用途
JP7093612B2 (ja) 2014-05-27 2022-06-30 アカデミア シニカ Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
JP6654781B2 (ja) 2014-08-29 2020-02-26 国立大学法人北海道大学 Ｋｉｒ２ｄｓ１に対するモノクローナル抗体
WO2017159088A1 (ja) * 2016-03-16 2017-09-21 国立大学法人京都大学 移植用培養細胞または培養組織の調製方法
US10858431B2 (en) * 2016-06-30 2020-12-08 Trellis Bioscience, Llc Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling
US10538592B2 (en) 2016-08-22 2020-01-21 Cho Pharma, Inc. Antibodies, binding fragments, and methods of use
US20210251994A1 (en) 2018-06-15 2021-08-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
CN109833480B (zh) * 2019-03-22 2021-09-07 中国科学院上海巴斯德研究所 靶向nk细胞免疫检查点治疗感染性疾病的方法
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US5539094A (en) 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
US5583034A (en) 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
US5808028A (en) 1994-05-24 1998-09-15 The United States Of America As Represented By The Department Of Health And Human Services Molecular clone of a P58 receptor protein and uses thereof
JP4926320B2 (ja) 1999-04-28 2012-05-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
KR100419555B1 (ko) 2000-05-29 2004-02-19 주식회사유한양행 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
DE602004030464D1 (de) 2003-07-02 2011-01-20 Innate Pharma Methode zur produktion und evaluierung der zytotoxizität von kir2dl nk-rezeptor antikörpern
EP1648507B1 (en) 2003-07-24 2017-01-25 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds

Also Published As

Publication number Publication date
JP2008526812A (ja) 2008-07-24
EP1835937B1 (en) 2012-04-11
US20140023646A1 (en) 2014-01-23
DK1835937T3 (da) 2012-07-23
WO2006072624A2 (en) 2006-07-13
EP1835937A2 (en) 2007-09-26
SI1835937T1 (sl) 2012-08-31
ATE552852T1 (de) 2012-04-15
JP5154949B2 (ja) 2013-02-27
PT1835937E (pt) 2012-06-25
PL1835937T3 (pl) 2012-09-28
WO2006072624A3 (en) 2006-11-16
US20090035305A1 (en) 2009-02-05
US8551483B2 (en) 2013-10-08
US9333255B2 (en) 2016-05-10
ES2384466T3 (es) 2012-07-05

Similar Documents

Publication Publication Date Title
CY1113182T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση ιογενους λοιμωξης
DK1578936T3 (da) Humane anti-IFN-gamma-neutraliserende antistoffer som selektive inhibitorer af IFN-gamma-vejen
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
WO2006110814A3 (en) Methods for treating diseases through inhibition the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
NO341586B1 (no) Fremgangsmåte for valg av et anti-naturlig drepe cellereseptor (NKR) antistoff
DE602007013618D1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
ATE548388T1 (de) An den interleukin-4-rezeptor bindende antikörper
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
DK2719708T3 (da) Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
EA201000424A1 (ru) Антитела к il-23
BR0212469A (pt) Método para multiplicação de vìrus em cultura de célula
BRPI0511187A (pt) método para tratar cáncer em um indivìduo
NO20070854L (no) Humane monoklonale antistoffer mot humant IL-4.
DE602006019977D1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
DE112004000961D2 (de) Verwendung von Wirksubstanzen zur Vorbeugung oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
EA202091974A1 (ru) Связывающие bcma антитела и их применение
CL2007002370A1 (es) Conjugado que consta de un anticuerpo anti-ccr5 y uno o mas peptidos antifusogenicos; composicion farmaceutica que lo comprende; metodo de preparacion; y su uso para tratar infecciones virales.
WO2022011110A3 (en) Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
ATE478707T1 (de) Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen
BR112023002234A2 (pt) Anticorpos sars-cov-2 para tratamento e prevenção de covid-19
EA200870263A1 (ru) Внутривенный способ лечения вирусной инфекции
GB0220257D0 (en) Vaccine